Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study
Drugs - Real World Outcomes · 2022-03 · 9 (1) · 63-78
DOI: 10.1007/s40801-021-00276-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs - Real World Outcomes, online erschienen am 29.08.2021. Verfasst von Nobuhiro Tsukada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi K.K..
Themen: Mobilisation
Abstract (Originalsprache)
BACKGROUND: Plerixafor was approved in Japan in 2016 for peripheral blood stem cell (PBSC) mobilization in autologous stem cell transplantation (A-SCT). OBJECTIVE: Our objective was to evaluate the safety and effectiveness of plerixafor in Japanese patients undergoing A-SCT for various indications in real-world practice. PATIENTS AND METHODS: This post-marketing surveillance study included Japanese patients initiating PBSC mobilization with plerixafor for A-SCT. Safety assessments included the incidence of adverse events (AEs) including serious AEs, adverse drug reactions (ADRs), and laboratory variables. Effectiveness assessments were the proportion of patients with the target CD34+ cell yield (≥2 × 106 cells/kg) ≤4 days after plerixafor administration and the number of days required to reach the target CD34+ cell yield. RESULTS: In total, 785 patients were registered, and the safety and effectiveness analysis sets comprised 764 and 717 patients, respectively. ADRs occurred in 12.2% of patients, with gastrointestinal disorders (5.5%), laboratory investigations (4.5%), and blood and lymphatic system disorders (3.0%) being the most common. A total of 71.1% of patients had the target CD34+ cell yield within ≤4 days of treatment, with a mean (standard deviation) of 1.3 (0.7) days to reach the target CD34+ cell yield. Over 80% of patients with a baseline CD34+ cell count >2 cells/μL had a target CD34+ cell yield within ≤4 days of treatment. CONCLUSIONS: This large post-marketing surveillance study provided real-world evidence detailing the safety and effectiveness of plerixafor for PBSC mobilization in Japanese patients undergoing A-SCT. Importantly, no new safety concerns were identified, and the safety profile of plerixafor was consistent with the established profile of this drug.
Autor:innen und Institutionen
- Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
- Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Division of Hematology/Oncology, Kanagawa Children's Medical Center, Kanagawa, Japan.
- Sanofi Genzyme Medical, Oncology Medical, Sanofi K.K., Tokyo, Japan.
- Medical Affairs, Post-Authorization Regulatory Studies, Sanofi K.K., Tokyo, Japan.
- Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan. iida@med.nagoya-cu.ac.jp.
Förderung
- Sanofi K.K.
Zitieren
APA
Tsukada, N., Nishikori, M., Goto, H., Kanamori, R., Nishina, S., Seto, T., & Iida, S. (2022). Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study. Drugs - Real World Outcomes, 9(1), 63-78. https://doi.org/10.1007/s40801-021-00276-1
Vancouver
Tsukada N, Nishikori M, Goto H, Kanamori R, Nishina S, Seto T, et al. Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study. Drugs - Real World Outcomes. 2022;9(1):63-78. doi:10.1007/s40801-021-00276-1
BibTeX
@article{Tsukada2022,
author = {Tsukada, Nobuhiro and Nishikori, Momoko and Goto, Hiroaki and Kanamori, Rie and Nishina, Satoshi and Seto, Takashi and Iida, Shinsuke},
title = {Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study},
journal = {Drugs - Real World Outcomes},
year = {2022},
volume = {9},
number = {1},
pages = {63--78},
doi = {10.1007/s40801-021-00276-1}
}
EUVIMED